Arvinas to Participate in Upcoming Investor Conferences
04 Março 2025 - 6:05PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that management will participate in
three upcoming investor conferences:
- Leerink Partners Global
Healthcare Conference 2025 on Tuesday, March 11. Andrew
Saik, Chief Financial Officer, and Randy Teel, Ph.D., Chief
Business Officer, will participate in a fireside chat. A live audio
webcast of the presentation will be available here and on the
Events and Presentations section of the Company’s website.
- Jefferies Biotech on the Beach Summit on
Wednesday, March 12. Andrew Saik, Chief Financial Officer, and
Randy Teel, Ph.D., Chief Business Officer, will participate in
one-on-one meetings.
- Barclays 27th Annual Global Healthcare
Conference on Thursday, March 13. Andrew Saik, Chief
Financial Officer, and Randy Teel, Ph.D., Chief Business Officer,
will participate in a fireside chat. A live audio webcast of the
presentation will be available here and on the Events and
Presentations section of the Company’s website.
About ArvinasArvinas (Nasdaq: ARVN) is a
clinical-stage biotechnology company dedicated to improving the
lives of patients suffering from debilitating and life-threatening
diseases. Through its PROTAC (PROteolysis TArgeting Chimera)
protein degrader platform, the Company is pioneering the
development of protein degradation therapies designed to harness
the body’s natural protein disposal system to selectively and
efficiently degrade and remove disease-causing proteins. Arvinas is
currently progressing multiple investigational drugs through
clinical development programs, including vepdegestrant, targeting
the estrogen receptor for patients with locally advanced or
metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for
relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting
LRRK2 for neurodegenerative disorders. Arvinas is headquartered in
New Haven, Connecticut. For more information about Arvinas, visit
www.arvinas.comand connect on LinkedIn and X.
Contacts Investors:Jeff
Boyle+1 (347) 247-5089Jeff.Boyle@arvinas.com
Media:Kirsten Owens+1 (203)
584-0307Kirsten.Owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Arvinas (NASDAQ:ARVN)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025